An 80-year-old man was admitted to our inpatient unit because of pneumonia. An ECG performed during fever (39°C) showed a regular rhythm, normal PR interval, RSR' with ST-elevation in V1/V3 leads with normal QRS duration. In particular, V2 lead showed a coved-type ST-segment, consistent with type-1 Brugada alteration (figure 1). The patient's clinical and family history was unremarkable for symptomatic arrhythmias, syncope or sudden death. An ECG performed with normal body temperature (36.5°C) showed ST-elevation in V1/V3 leads, with a saddleback-type ST-segment in V2, consistent with type-2 Brugada alteration (figure 2). Brugada syndrome, first described in 1992, 1 is a clinical entity characterised by typical ECG alterations associated with a high risk of sudden cardiac death. These ECG patterns can be seen spontaneously, induced by sodium channel blocking agents or by hyperthermia. One of the proposed pathological mechanisms is an alteration in the sodium 
DESCRIPTION
An 80-year-old man was admitted to our inpatient unit because of pneumonia. An ECG performed during fever (39°C) showed a regular rhythm, normal PR interval, RSR' with ST-elevation in V1/V3 leads with normal QRS duration. In particular, V2 lead showed a coved-type ST-segment, consistent with type-1 Brugada alteration (figure 1). The patient's clinical and family history was unremarkable for symptomatic arrhythmias, syncope or sudden death. An ECG performed with normal body temperature (36.5°C) showed ST-elevation in V1/V3 leads, with a saddleback-type ST-segment in V2, consistent with type-2 Brugada alteration (figure 2). Brugada syndrome, first described in 1992, 1 is a clinical entity characterised by typical ECG alterations associated with a high risk of sudden cardiac death. These ECG patterns can be seen spontaneously, induced by sodium channel blocking agents or by hyperthermia. One of the proposed pathological mechanisms is an alteration in the sodium 2 It has been reported that fever can induce a Brugada-type ECG pattern in asymptomatic patients disclosing Brugada syndrome, even outperforming flecainide test.
3 In this connection, in our patient the flecainide challenge test was not performed since the patient did not give his consent. However, concomitant with another episode of fever, a new ECG was recorded ( figure 3) , showing the reappearance of type-1 Brugada alterations.
Since febrile illness, unmasking Brugada electrical disturbances, could precipitate ventricular arrhythmias, it is important to aggressively reduce body temperature in order to minimise the risk of sudden cardiac death.
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